Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661966 | 1.00 | KDM4E (0.37) | KDM4EHTR1AACHEPDE4BEGFR | |
| SCHEMBL10192603 | 0.89 | DPP4 (0.37) | KDM4EHTR1AEGFRMTNR1BMTNR1A | |
| SCHEMBL660046 | 0.87 | EGFR (0.38) | KDM4EHTR1AACHEPDE4BEGFR | |
| SCHEMBL660146 | 0.85 | PDE4B (0.41) | HTR1AACHEPDE4BEGFRTP53 | |
| SCHEMBL660563 | 0.81 | HTT (0.50) | HTR1AACHEEGFRHTT | |
| SCHEMBL658213 | 0.80 | ALDH1A1 (0.51) | TP53HTTMEN1KMT2A | |
| SCHEMBL16094448 | 0.75 | MERTK (0.46) | PDE4BMEN1KMT2A | |
| SCHEMBL4715183 | 0.73 | MEN1 (0.45) | KDM4EADORA2AMEN1KMT2A | |
| SCHEMBL16094781 | 0.72 | KMT2A (0.44) | ADORA2AHTTMEN1KMT2A | |
| SCHEMBL4712409 | 0.69 | MEN1 (0.44) | KDM4EHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS HOLDINGS INC (US) | 2014-12-11 | — | — | US | disclosed |
| US-8674095-B2 | Compounds for treating neuropsychiatric conditions | AFRAXIS HOLDINGS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | AFRAXIS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| EP-2504011-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | Afraxis, Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| EP-2485733-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | Afraxis, Inc. (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| EP-2453896-A2 | METHODS FOR TREATING SCHIZOPHRENIA | Afraxis, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS INC. (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2011063415-A2 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | AFRAXIS, INC. (US) | 2011-05-26 | — | — | WO | disclosed |
| WO-2011044537-A2 | METHODS FOR TREATING ALZHEIMER'S DISEASE | AFRAXIS, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| WO-2011009097-A2 | METHODS FOR TREATING SCHIZOPHRENIA | AFRAXIS, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2010071846-A2 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | AFRAXIS, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270844-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | PSEN2, MAPT, PSEN1 | KDM4E 2679/4885HTR1A 2841/4885ACHE 39/4885 |
| US-20140364430-A1 | METHODS FOR TREATING SCHIZOPHRENIA | GRIN2A, GRIN2C, GRIN3A | KDM4E 3382/4885HTR1A 1117/4885ACHE 953/4885 |
| US-20130096115-A1 | METHODS FOR TREATING AUTISM | PAK2, PAK3, PAK4 | KDM4E 1647/4885HTR1A 1237/4885ACHE 479/4885 |
| US-20120046283-A1 | COMPOUNDS FOR TREATING NEUROPSYCHIATRIC CONDITIONS | PAK2, PAK5, PAK6 | KDM4E 1764/4885HTR1A 96/4885ACHE 1263/4885 |
| US-20120184547-A1 | METHODS FOR TREATING SCHIZOPHRENIA | PAK2, PAK3, PAK4 | KDM4E 2994/4885HTR1A 1144/4885ACHE 587/4885 |
| US-20130059824-A1 | METHODS FOR TREATING MILD COGNITIVE IMPAIRMENT | CHAT, PSEN2, PAK2 | KDM4E 2433/4885HTR1A 1180/4885ACHE 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.